《中国肝细胞癌免疫检查点抑制剂联合治疗多学科专家共识（2023年版）》
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).
作者信息
Liu Xiufeng, Lu Yinying, Zhou Weiping, Peng Tao, Zhou Jie, Bi Huaqiang, Xia Feng, Chen Xiaoping
机构信息
Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
Comprehensive Liver Cancer Center, 5th Medical Center of PLA General Hospital, Beijing, China.
出版信息
Liver Cancer. 2024 Jan 16;13(4):355-375. doi: 10.1159/000535496. eCollection 2024 Aug.
Abstract
BACKGROUND
Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC.
SUMMARY
To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "" on the basis of the 2021 edition.
KEY MESSAGES
This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.
摘要
背景
基于免疫检查点抑制剂（ICI）的肝细胞癌（HCC）联合治疗模式在临床研究和实践中已取得显著疗效，成为不可切除HCC治疗的主要手段。
总结
为了更好地帮助临床医生合理、有效且安全地使用联合免疫治疗药物和方案，编辑委员会与该领域的多学科专家进行了讨论，采用“德尔菲”共识形成方法，并最终在2021年版的基础上修订完成了本《共识》。
关键信息
本共识主要聚焦基于ICI的联合治疗临床实践的原则和方法，旨在根据最新研究和专家经验总结临床应用建议，为临床医生提供应用指导。
相似文献
1
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).《中国肝细胞癌免疫检查点抑制剂联合治疗多学科专家共识（2023年版）》
Liver Cancer. 2024 Jan 16;13(4):355-375. doi: 10.1159/000535496. eCollection 2024 Aug.
2
[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)].《中国肝细胞癌联合免疫治疗多学科专家共识（2023年版）》
Zhonghua Gan Zang Bing Za Zhi. 2023 Jan 20;31(1):16-34. doi: 10.3760/cma.j.cn501113-20221215-00602.
3
[Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].《中国肝细胞癌免疫检查点抑制剂联合免疫治疗多学科专家共识（2021年版）》
Zhonghua Gan Zang Bing Za Zhi. 2021 Jul 20;29(7):636-647. doi: 10.3760/cma.j.cn501113-20210604-00261.
4
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).《中国肝细胞癌免疫治疗专家共识（2021年版）》
Liver Cancer. 2022 Jul 20;11(6):511-526. doi: 10.1159/000526038. eCollection 2022 Dec.
5
[Chinese expert consensus on neoadjuvant therapy for hepatocellular carcinoma (2023 edition)].《肝细胞癌新辅助治疗中国专家共识（2023年版）》
Zhonghua Wai Ke Za Zhi. 2023 Dec 1;61(12):1035-1045. doi: 10.3760/cma.j.cn112139-20230914-00121.
6
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].《中国晚期非小细胞肺癌驱动基因变异免疫治疗专家共识（2023年版）》
Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):717-740. doi: 10.3760/cma.j.cn112152-20230420-00179.
7
Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review.免疫治疗时代肝细胞癌的病理评估：一篇叙述性综述
Hepatobiliary Surg Nutr. 2024 Jun 1;13(3):472-493. doi: 10.21037/hbsn-22-527. Epub 2023 Apr 4.
8
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.日本肝细胞癌的管理：2021年更新版日本肝脏学会共识声明与建议
Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19.
9
[Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].基于免疫检查点抑制剂与抗血管生成靶向药物联合的晚期肝细胞癌转化治疗后序贯手术专家共识（2024年版）
Zhonghua Wai Ke Za Zhi. 2024 Nov 1;62(11):984-995. doi: 10.3760/cma.j.cn112139-20240814-00245.
10
[Immunotherapy clinical application and research prospects for liver cancer].[肝癌的免疫治疗临床应用及研究前景]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jul 20;29(7):615-617. doi: 10.3760/cma.j.cn501113-20210622-00297.
引用本文的文献
1
Bibliometric and visualized analysis of global distribution and research frontiers in tumor immune escape.肿瘤免疫逃逸全球分布与研究前沿的文献计量学及可视化分析
Front Immunol. 2025 Jun 5;16:1586120. doi: 10.3389/fimmu.2025.1586120. eCollection 2025.
2
Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation.多学科肿瘤委员会与肝移植术后肝细胞癌患者生存率的提高相关。
World J Clin Oncol. 2025 Apr 24;16(4):100729. doi: 10.5306/wjco.v16.i4.100729.
本文引用的文献
1
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.一项关于经动脉化疗栓塞疗法联合乐伐替尼治疗不可切除中期肝细胞癌的2期前瞻性多中心单臂试验：TACTICS-L试验
Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.
2
A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma.多学科治疗策略联合转化手术治疗肝细胞癌。
Anticancer Res. 2023 Apr;43(4):1761-1766. doi: 10.21873/anticanres.16329.
3
Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.信迪利单抗联合乐伐替尼用于中/局部晚期肝细胞癌的转化治疗：一项2期研究。
Front Oncol. 2023 Feb 16;13:1115109. doi: 10.3389/fonc.2023.1115109. eCollection 2023.
4
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.替雷利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者（RATIONALE-208）：一项多中心、非随机、开放标签的2期试验。
Liver Cancer. 2022 Oct 4;12(1):72-84. doi: 10.1159/000527175. eCollection 2023 Feb.
5
Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.比较单独使用酪氨酸激酶抑制剂或与程序性细胞死亡蛋白-1 抑制剂联合治疗的肝细胞癌患者乙型肝炎病毒再激活情况。
Hepatol Int. 2023 Apr;17(2):281-290. doi: 10.1007/s12072-022-10450-4. Epub 2022 Dec 29.
6
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.基线ALBI评分和血清甲胎蛋白的早期变化可预测接受阿替利珠单抗-贝伐单抗治疗的肝癌患者的预后。
Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14.
7
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.免疫疗法毒性的管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18.
8
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.酪氨酸激酶抑制剂联合抗 PD-1 抗体治疗后行肝切除术治疗不可切除肝细胞癌患者。
Ann Surg Oncol. 2023 May;30(5):2782-2790. doi: 10.1245/s10434-022-12530-z. Epub 2022 Sep 30.
9
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.TACTICS的最终结果：一项随机、前瞻性试验，比较经动脉化疗栓塞联合索拉非尼与单纯经动脉化疗栓塞治疗不可切除肝细胞癌患者的疗效。
Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul.
10
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).仑伐替尼联合经动脉化疗栓塞术作为晚期肝细胞癌一线治疗的III期随机临床试验（LAUNCH）
J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.
Zotero 插件